Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1978–1986. doi: 10.1054/bjoc.2001.2167

Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues

V C-L Lin 1, S E Aw 1, E H Ng 2, E H-L Ng 2, M G-K Tan 1
PMCID: PMC2364017  PMID: 11747343

Abstract

Progesterone antagonist RU486 (mifepristone) has been implicated for many anti-neoplastic and obstetrical applications. But the compound has demonstrated undesired agonist-like effect depending on cell, tissue and species studied. Using PR-transfected breast cancer cells MDA-MB-231, this report describes the similarities and differences between progesterone- and RU486-mediated effects on cell growth, cell differentiation and, at the molecular level, on the activation of p44/p42 MAP kinases (MAPK). Like progesterone, RU486 inhibited cells growth by arresting the cells in G0/G1 phase of the cell cycle. In contrast to progesterone that induced cell spreading, RU486 induced a multipolar, stellate morphology. RU486-treated cells showed no increase of stress fibers, nor was there any increase of focal adhesions as progesterone-treated cells did. Furthermore, despite of the fact that both compounds inhibited cell growth, RU486 significantly stimulated the activation of p44/p42 MAP kinases whereas progesterone markedly inhibited the activation. Nonetheless, the effects of RU486 were PR-mediated and RU486 was able to antagonize the effect of progesterone on cell growth and focal adhesion. In conclusion, RU486 can act not only as a progesterone antagonist, a progesterone agonist but also induced morphological and molecular changes that were distinct from progesterone-mediated effects in PR-transfected MDA-MB-231 cells. The non-progesterone-like effect of RU486 may be mediated through a pathway that is different from the progesterone-mediated pathway, or it is the result of a blockade of certain critical step(s) in the progesterone-mediated pathway. In any case, undesired side effects of antiprogestin may create clinical complications. PR-transfected MDA-MB-231 breast cancer cells provide a model for studying the functions of progesterone analogues.© 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: RU486 morphology cell growth p42/p44 MAPK PR-transfected MDA-MB-231

Full Text

The Full Text of this article is available as a PDF (171.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck C. A., Zhang Y., Weigel N. L., Edwards D. P. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem. 1996 Jan 12;271(2):1209–1217. doi: 10.1074/jbc.271.2.1209. [DOI] [PubMed] [Google Scholar]
  2. Bocquel M. T., Ji J., Ylikomi T., Benhamou B., Vergezac A., Chambon P., Gronemeyer H. Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J Steroid Biochem Mol Biol. 1993 Apr;45(4):205–215. doi: 10.1016/0960-0760(93)90334-s. [DOI] [PubMed] [Google Scholar]
  3. Cadepond F., Ulmann A., Baulieu E. E. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997;48:129–156. doi: 10.1146/annurev.med.48.1.129. [DOI] [PubMed] [Google Scholar]
  4. Conneely O. M., Mulac-Jericevic B., Lydon J. P., De Mayo F. J. Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97–103. doi: 10.1016/s0303-7207(01)00465-8. [DOI] [PubMed] [Google Scholar]
  5. Dent P., Jarvis W. D., Birrer M. J., Fisher P. B., Schmidt-Ullrich R. K., Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia. 1998 Dec;12(12):1843–1850. doi: 10.1038/sj.leu.2401222. [DOI] [PubMed] [Google Scholar]
  6. Fuhrmann U., Hess-Stumpp H., Cleve A., Neef G., Schwede W., Hoffmann J., Fritzemeier K. H., Chwalisz K. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010–5016. doi: 10.1021/jm001000c. [DOI] [PubMed] [Google Scholar]
  7. Gaillard R. C., Herrmann W. Utilisation clinique du RU 486: contrôle du cycle menstruel et effet sur l'axe hypophyso-surrénalien. Ann Endocrinol (Paris) 1983;44(5):345–346. [PubMed] [Google Scholar]
  8. Gravanis A., Schaison G., George M., de Brux J., Satyaswaroop P. G., Baulieu E. E., Robel P. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab. 1985 Jan;60(1):156–163. doi: 10.1210/jcem-60-1-156. [DOI] [PubMed] [Google Scholar]
  9. Guiochon-Mantel A., Loosfelt H., Ragot T., Bailly A., Atger M., Misrahi M., Perricaudet M., Milgrom E. Receptors bound to antiprogestin from abortive complexes with hormone responsive elements. Nature. 1988 Dec 15;336(6200):695–698. doi: 10.1038/336695a0. [DOI] [PubMed] [Google Scholar]
  10. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998 Jan 23;279(5350):509–514. doi: 10.1126/science.279.5350.509. [DOI] [PubMed] [Google Scholar]
  11. Herrmann W., Wyss R., Riondel A., Philibert D., Teutsch G., Sakiz E., Baulieu E. E. Effet d'un stéroide anti-progestérone chez la femme: interruption du cycle menstruel et de la grossesse au début. C R Seances Acad Sci III. 1982 May 17;294(18):933–938. [PubMed] [Google Scholar]
  12. Horwitz K. B., Tung L., Takimoto G. S. Novel mechanisms of antiprogestin action. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):9–17. doi: 10.1016/0960-0760(95)00035-x. [DOI] [PubMed] [Google Scholar]
  13. Jackson T. A., Richer J. K., Bain D. L., Takimoto G. S., Tung L., Horwitz K. B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol. 1997 Jun;11(6):693–705. doi: 10.1210/mend.11.6.0004. [DOI] [PubMed] [Google Scholar]
  14. Kastner P., Bocquel M. T., Turcotte B., Garnier J. M., Horwitz K. B., Chambon P., Gronemeyer H. Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms. J Biol Chem. 1990 Jul 25;265(21):12163–12167. [PubMed] [Google Scholar]
  15. Klein-Hitpass L., Cato A. C., Henderson D., Ryffel G. U. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 1991 Mar 25;19(6):1227–1234. doi: 10.1093/nar/19.6.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lin V. C., Ng E. H., Aw S. E., Tan M. G., Ng E. H., Bay B. H. Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA. Mol Endocrinol. 2000 Mar;14(3):348–358. doi: 10.1210/mend.14.3.0426. [DOI] [PubMed] [Google Scholar]
  17. Lin V. C., Ng E. H., Aw S. E., Tan M. G., Ng E. H., Chan V. S., Ho G. H. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res. 1999 Feb;5(2):395–403. [PubMed] [Google Scholar]
  18. Meyer M. E., Pornon A., Ji J. W., Bocquel M. T., Chambon P., Gronemeyer H. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J. 1990 Dec;9(12):3923–3932. doi: 10.1002/j.1460-2075.1990.tb07613.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nordeen S. K., Bona B. J., Moyer M. L. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol. 1993 Jun;7(6):731–742. doi: 10.1210/mend.7.6.8395651. [DOI] [PubMed] [Google Scholar]
  20. Rocereto T. F., Saul H. M., Aikins J. A., Jr, Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol. 2000 Jun;77(3):429–432. doi: 10.1006/gyno.2000.5789. [DOI] [PubMed] [Google Scholar]
  21. Sartorius C. A., Groshong S. D., Miller L. A., Powell R. L., Tung L., Takimoto G. S., Horwitz K. B. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 1994 Jul 15;54(14):3868–3877. [PubMed] [Google Scholar]
  22. Sebolt-Leopold J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene. 2000 Dec 27;19(56):6594–6599. doi: 10.1038/sj.onc.1204083. [DOI] [PubMed] [Google Scholar]
  23. Smith C. L., Nawaz Z., O'Malley B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997 Jun;11(6):657–666. doi: 10.1210/mend.11.6.0009. [DOI] [PubMed] [Google Scholar]
  24. Spitz I. M., Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids. 2000 Oct-Nov;65(10-11):807–815. doi: 10.1016/s0039-128x(00)00194-x. [DOI] [PubMed] [Google Scholar]
  25. Takimoto G. S., Graham J. D., Jackson T. A., Tung L., Powell R. L., Horwitz L. D., Horwitz K. B. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):45–50. doi: 10.1016/s0960-0760(98)00148-4. [DOI] [PubMed] [Google Scholar]
  26. Truss M., Bartsch J., Beato M. Antiprogestins prevent progesterone receptor binding to hormone responsive elements in vivo. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11333–11337. doi: 10.1073/pnas.91.24.11333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tung L., Mohamed M. K., Hoeffler J. P., Takimoto G. S., Horwitz K. B. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol. 1993 Oct;7(10):1256–1265. doi: 10.1210/mend.7.10.8123133. [DOI] [PubMed] [Google Scholar]
  28. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  29. el-Ashry D., Oñate S. A., Nordeen S. K., Edwards D. P. Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol. 1989 Oct;3(10):1545–1558. doi: 10.1210/mend-3-10-1545. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES